# Wenzhou Capital

> Wenzhou Capital is a VC fund in Xuhui backing Health Care, Medical and Pharmaceutical. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Xuhui, China
- Total investments: 8
- Last investment: Nov 2025
- Lead investor: 38%
- Last updated: Aug 2026
- Website: http://www.wenzhoucapital.com

Wenzhou Capital is a mixed-ownership professional investment organization specializing in biopharmaceutical investing.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 63% |
| Medical | 4 | 50% |
| Pharmaceutical | 4 | 50% |
| Biotechnology | 3 | 38% |
| Therapeutics | 2 | 25% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 63% |
| Seed | 1 | 13% |
| Series A | 1 | 13% |
| Series C | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 6 | 75% |
| United States | 2 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Puguang Bio | Puguang Bio is a developer of in vitro medical diagnostic systems. |  | Series B | Nov 27, 2025 |  |
| Subtle Medical | Subtle Medical is a healthcare technology company that provides AI-powered medical imaging. Its products, SubtlePET and SubtleMR, are FDA Cleared and CE Marked AI product that enhances images in PET and MR exams aimed for faster & safer workflow.The company's SubtleGAD technology is also awarded by RSNA and a $1.6M NIH SBIR Grant tofacilitate the adoption using AI to make imaging exams safer. They provide a vendor-agnostic AI infrastructure powering its products and providing service and analytics to clinical imaging providers.Subtle Medical's goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. | $10M | Series B | May 13, 2024 |  |
| AnDiConBio | developer of respiratory anti-infection drugs, offering high-potential, low-risk products like new anti-influenza and oral anti-new coronavirus. | $27.6M | Series A | Apr 29, 2024 |  |
| Minova Pharma | Minova Pharma focuses on the development of novel medications in the spiritual and medicinal beauty domains. |  | Series B | Jan 05, 2024 |  |
| Jinfang Pharmaceutical | Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies. | $77.1M | Series C | Dec 31, 2021 |  |
| Vision Pharmaceutical | Vision Pharmaceutical l is a high-tech enterprise dedicated to the research and development of anti-drug resistance drugs. | $15.7M | Seed | Dec 28, 2021 |  |
| TYK Medicines | It is an international innovative biotechnology high-tech company focuses on the research and development of new tumor drugs. | $62.2M | Series B | May 23, 2021 |  |
| Phanes Therapeutics | Phanes Therapeutics is a biotech company focused on discovery and development of therapeutics for solid tumors and eye diseases. Their extensive experience and deep scientific knowledge strongly position us to discover and advance robust therapeutic molecules. Through scientific innovation, we deliver better treatment options for patients. Theirmission is to relentlessly seek scientific and technological solutions to improve the lives of patients globally. | $40M | Series B | May 07, 2021 |  |

8 of 8 investments shown.

## Co-investors
- [Dyee Capital](https://shizune.co/investors/profile/dyee-capital) — VC Fund, 2 deals together
- [Huagai Capital](https://shizune.co/investors/profile/huagai-capital) — VC Fund, 2 deals together
- [SAV (Scale Asia Ventures)](https://shizune.co/investors/profile/scale-asia-ventures) — VC Fund, 2 deals together
- [ABC International](https://shizune.co/investors/profile/abc-international) — VC Fund, 1 deal together
- [Baidu Ventures](https://shizune.co/investors/profile/baidu-ventures) — VC Fund, 1 deal together
- [BlueRun Ventures](https://shizune.co/investors/profile/bluerun-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Wenzhou Capital invest in?

Wenzhou Capital invests primarily in Health Care, Medical and Pharmaceutical startups, most often at Series B and Seed stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Wenzhou Capital last invest?

The most recent investment recorded for Wenzhou Capital closed in Nov 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co